NCI Client: Alcresta Therapeutics introduces RELiZORB

NCI Client: Alcresta Therapeutics introduces RELiZORB

Alcresta Therapeutics’ RELiZORB™ Increases Fat Absorption in Adult and Pediatric Patients with Cystic Fibrosis Receiving Enteral Nutrition

RELiZORB significantly increased plasma levels of DHA and EPA fatty acids and patients report a decrease in the frequency and severity of gastrointestinal symptoms


RELiZORB is a first-of-its kind digestive enzyme cartridge designed to mimic the function of pancreatic lipase. RELiZORB is designed for use by patients receiving enteral tube feeding who have trouble breaking down and absorbing fats. RELiZORB was developed using Alcresta Therapeutics’ proprietary enzyme immobilization technology.  The active ingredient in RELiZORB is the digestive enzyme lipase, attached to polymeric carriers, together called iLipase.

As the enteral tube feeding formula passes through RELiZORB it makes contact with the iLipase, and the fat in the formula is broken down to its absorbable form (fatty acids and monoglycerides) prior toingestion. The iLipase remains in the cartridge and does not become part of what is ingested. RELiZORB has been shown to break down more than 90 percent of fats in most enteral feeding tube formulas tested, including the most difficult to break down LCPUFAs, such as DHA, EPA, and arachidonic acid, which are critical for growth and development.


Over time, decreased fat absorption can lead to deficiencies in important fatty acids, such as omega-3 fatty acids. A balanced ratio of omega-3 to omega-6 fatty acids is beneficial in maintaining normal development and overall health.

RELiZORB easily connects in-line with enteral feeding systems. Simple for clinicians, caregivers, and patients to connect.


Share this post

Schedule FREE Webinar